THERAPY DOSSIER · th-eb0bcdb6641e

A-68930

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27067657 ↗2016Reported benefit

Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury.

RatSpinal cord injuryUnspecifiedSprague-DawleyfemaleAfter spinal cord injury, outcomes assessed 72 h post injury

Model: Spinal cord injury induced acute lung injury

A-68930 inhibited NLRP3 inflammasome activation, lowered proinflammatory cytokines and myeloperoxidase activity, and attenuated pulmonary oedema and lung histopathology at 72 h after spinal cord injury.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…